Cost–effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia

Author： Sorich Michael J   Horowitz John D   Sorich Wassana   Wiese Michael D   Pekarsky Brita   Karnon Jonathan D  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.16, 2013-12, pp. : 2013-2021

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation

By Panattoni Laura   Brown Paul M.   >   Webster Mark   Gladding Patrick  

PharmacoEconomics, Vol. 30, Iss. 11, 2012-11 ,pp. : 1067-1084

Adis International

Access to resources Recommend Favorite

Beyond CYP2C19 – A New Chapter in Clopidogrel Pharmacogenomics

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 41, Iss. 1, 2011-03 ,pp. : 14-16

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 8, Iss. 4, 2010-12 ,pp. : 268-272

Bentham Science Publishers

Access to resources Recommend Favorite

Cytochrome P450 2C19 (CYP2C19) genotype appears to affect the efficacy of omeprazole

By  

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of ticagrelor in acute coronary syndromes

By Henriksson Martin   Janzon Magnus  

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Iss. 1, 2013-02 ,pp. : 9-18

Informa Healthcare

Access to resources Recommend Favorite